Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/21645515.2020.1793712 http://scihub22266oqcxt.onion/10.1080/21645515.2020.1793712 32881641!8641615!32881641     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32881641&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Hum+Vaccin+Immunother 2020 ; 16 (12): 2973-2979 Nephropedia Template TP {{tp|p=32881641|t=2020. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19 |pdf=|usr=}}{{32881641}} gab.com Text Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19 JO: Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=32881641 #FOAvip The emergence of the COVID-19 pandemic has resulted in a very large number of infections and high number of mortality. There is no specific therapeutic options that are approved for clinical use. Administration of convalescent plasma as a possible therapy was used in the case of viral pneumonia including SARS and influenza. There have been multiple studies of COVID-19 patients utilizing convalescent plasma. These studies employed different dosage levels and different regiments, were observational and lacked control arms, and had variable outcomes. Two of these studies used plasma with anti-SARS-CoV-2 titers of >1:640 to >1:1000. A recent randomized controlled clinical trial showed no benefit of convalescent plasma in patients with severe diseases. However, the study was terminated early and thus further clinical trials are needed to show efficacy in patients with COVID-19 infection. Twit Text FOAVip Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19 ????Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=32881641 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32881641 #FOAvip English Wikipedia <ref>{{Cite pmid|32881641}}</ref> Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19 #MMPMID32881641 Al-Tawfiq JA; Arabi Y Hum Vaccin Immunother 2020[Dec]; 16 (12): 2973-2979 PMID32881641show ga The emergence of the COVID-19 pandemic has resulted in a very large number of infections and high number of mortality. There is no specific therapeutic options that are approved for clinical use. Administration of convalescent plasma as a possible therapy was used in the case of viral pneumonia including SARS and influenza. There have been multiple studies of COVID-19 patients utilizing convalescent plasma. These studies employed different dosage levels and different regiments, were observational and lacked control arms, and had variable outcomes. Two of these studies used plasma with anti-SARS-CoV-2 titers of >1:640 to >1:1000. A recent randomized controlled clinical trial showed no benefit of convalescent plasma in patients with severe diseases. However, the study was terminated early and thus further clinical trials are needed to show efficacy in patients with COVID-19 infection. |Antibodies, Viral/immunology[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/epidemiology/immunology/*therapy[MESH] |Coronavirus Infections/epidemiology/immunology/*therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH]Convalescent plasma therapy for coronavirus infection: experience from(epmc).pdf DeepDyve Pubget Overpricing